Demonstrating efficacy of ISIS 301012 in patients with FH may lead to an advance in therapy for these desperately ill patients and establish ISIS 301012 as a powerful new cholesterol-lowering drug. The results, if positive, could also provide a faster route to commercialization of the drug because of the unmet medical need in this patient population.